Back to Search
Start Over
Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.
- Source :
-
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Jun 21; Vol. 15, pp. 17588359231173181. Date of Electronic Publication: 2023 Jun 21 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC).<br />Objective: Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARPi.<br />Design: Retrospective cohort study.<br />Patients and Methods: The study involved 96 consecutive, pretreated, platinum-sensitive advanced OC patients. Demographics and clinical data were retrieved from clinical records. PFS and overall survival (OS) were calculated from the start of PARPi.<br />Results: Germline BRCA mutation was investigated in all cases. Platinum-based chemotherapy before PARPi maintenance therapy included pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) in 46 patients (48%) and other platinum-based chemotherapy in 50 patients (52%). During a median follow-up of 22 months from the beginning of PARPi therapy, 57 patients relapsed (median PFS: 12 months) and 64 patients died (median OS: 23 months). During multivariable analysis, receiving PLD-Ox before PARPi was associated with improved PFS [hazard ratio (HR): 0.46, 95% CI: 0.26-0.82] and OS (HR: 0.48, 95% CI: 0.27-0.83). In 36 BRCA-mutated patients, PLD-Ox was associated with improved PFS (2-year PFS: 70.0% versus 25.0%, p = 0.02).<br />Conclusion: Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup.<br />Competing Interests: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2023.)
Details
- Language :
- English
- ISSN :
- 1758-8340
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Therapeutic advances in medical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 37360767
- Full Text :
- https://doi.org/10.1177/17588359231173181